Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results

benzinga.com/news/health-care/25/06/45908647/biogen-ucb-take-a-leap-in-lupus-with-promising-phase-3-results

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP).
The companies released topline results in September 2024.
UCB and Biogen…

This story appeared on benzinga.com, 2025-06-12 15:33:15.
The Entire Business World on a Single Page. Free to Use →